Is this you?
Request access for Conquest Research with your @conquestresearch.com work email. Intera will contact you to verify and set up your account — nothing auto-publishes.
Intera lens
ICP 7Lift (cardio sample) 0.24Recruit soph 0.43
Quality Scorecard (1–100)
Overall62Recruit49Ops70Sponsor63Ther67
Performance (observed)
Historical trials
152
Completed
49
Terminated/Withdrawn
17
Completion rate
74%
Active now
81
Phase 2
60
Phase 3
85
Realized enrollment
147,733
First study year
1999
Years active
27
Match confidence
high
Enrollment velocity (inf)
5,472
Therapeutic
Areas
Dermatology, Gastrointestinal, Metabolic Disorders, Neurology, Orthopedics, Rheumatology, Psychiatry, Sleep Disorders
Specialties
Neurology (Alzheimer's, Parkinson's, MS, neuropathy, migraines), Orthopedics, Rheumatology, Dermatology, Sleep, Psychiatry, Gastrointestinal, Metabolic, Pain
Breadth (conditions)
168
Languages
English + Spanish (detected)
States
Florida, Georgia, Virginia
Recruitment (web observed)
Trial Finder
Yes
Recruitment pages
Yes
Advertises recruitment
Yes
Capability notes
High - Multimedia advertising, community events, physician referrals
Relationships
Sponsors
Eli Lilly and Company; Novartis Pharmaceuticals; AbbVie; Annovis Bio Inc.; Amgen; Novo Nordisk A/S
CROs
Novotech (Australia) Pty Limited; Parexel; Premier Research; Syneos Health
Owner / parent
Independent
Funding
PE: Reynolda Equity Partners (Oct 2023 acquisition)
Acquisitions
Acquired NeuroTrials (Dec 2025)
Expansion
Y (acquired NeuroTrials in Dec 2025)
Capacity & people
Investigators
—
Coordinators
—
CEO
Unknown
VP Clinical Ops
Unknown
VP Site Ops
Unknown
VP Recruitment
Unknown
Emails
unitedstates@bitrialsupport.com, info@conquestresearch.com
Tech & DCT
eSource
Yes
Builds tech
Unknown
Tech stack
Evolving technologies and e-solutions for trial efficiency
Recruiting visible
Y
Notes
ClinicalTrials.gov validation: 8 active recruiting cardiometabolic trials. Multi-location network with collaborative partnerships across Central Florida and East Coast. Emphasizes innovation with evolving technologies. Broad therapeutic mix supports recruitment demand.
Recommendation features (sample indication)
Ind fit 0.42Liftability 0.24Overall62
FUTURE MOAT: absolute enrollment rates, funnel CPR, measured SSU, screen-fail reasons.